Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, ...
Paso Robles Daily News1d
Eagle Athlete of the Week: Boston Matszewicz
Congrats to Boston Matszewicz for breaking our decade-old school record in 100 Breaststroke! – Templeton High School […] ...
Duchenne muscular dystrophy's impact on the brain may be reversible
New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...
Neurology Advisor2d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
Mirage News2d
Duchenne's Brain Impact May Be Reversible
New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...
WPBN3d
Reed City family seeks community help to fund wheelchair-accessible van for sons with DMD
A Reed City family is partnering with the Jett Foundation to help raise money for a wheelchair-accessible van.14-year-old ...
The American Journal of Managed Care3d
WVE-N531 Shows Functional Benefits, Muscle Damage Reversal in DMD
WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...
Muscular Dystrophy News3d
MDA 2025: Duvyzat delays walking loss, lessens lung function decline
Long-term treatment with Duvyzat (givinostat) may help delay the loss of walking ability and lessen the decline in lung ...
The Pharma Letter3d
Wave Life releases positive Phase II results for WVE-N531 in DMD
Cambridge, USA-based RNS specialist Wave Life Sciences (Nasdaq: WVE) has announced positive data from the Phase II FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being ...
Managed Healthcare Executive3d
Death of Elevidys Patient Rattles Duchenne Community
The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531
Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...